section name header

Evidence summaries

Antiretroviral Post-Exposure Prophylaxis (Pep) for Occupational HIV Exposure

Zidovudine may be effective as post-exposure prophylaxis (PEP) for occupational HIV exposure, but combinations of two or three antiretroviral drugs are recommended due to their success in treating HIV-infected individuals Level of evidence: "C"

A Cochrane review [Abstract] 1 included only 1 case - control study with a total of 33 cases and 679 controls. No randomized controlled trials were identified. HIV transmission was significantly associated with deep injury (OR 15, 95% CI 6.0 to 41), visible blood on the device (OR 6.2, 95% CI 2.2 to 21), procedures involving a needle placed in the source patient's blood vessel (OR 4.3, 95% CI 1.7 to 12), and terminal illness in the source patient (OR 5.6, 95% CI 2.0 to 16). After controlling for these risk factors, no differences were detected in the rates at which cases and controls were offered post-exposure prophylaxis with zidovudine. However, cases had significantly lower odds of having taken zidovudine after exposure compared to controls (OR 0.19, 95%CI 0.06 to 0.52). No studies were found that evaluated the effect of two or more antiretroviral drugs for occupational PEP.

Comment: It is highly unlikely that a definitive placebo-controlled trial will ever be conducted, and, therefore, on the basis of results from a single case-control study, a four-week regimen of PEP should be initiated as soon as possible after exposure, depending on the risk of seroconversion. Due to the success of combination therapies in treating HIV-infected individuals, a combination of antiretroviral drugs should be used for PEP.

References

  • Young TN, Arens FJ, Kennedy GE, Laurie JW, Rutherford G. Antiretroviral post-exposure prophylaxis (PEP) for occupational HIV exposure. Cochrane Database Syst Rev 2007 Jan 24;(1):CD002835. [PubMed]

Primary/Secondary Keywords